Please wait a minute...
Traditional Medicine Research  2017, Vol. 2 Issue (1): 41-50    DOI: 10.12032/TMR201705036
Clinical Research     
Analysis on the principles of differentiation and prescription of traditional Chinese medicine in the treatment of cancerous fever
Xu Wei1, Chai Ni1, Cheng Yue-Lei1, Yang Qiong1, Zhu Hui-Rong1,*()
Department of Medical Oncology, Shuguang Hospital Affiliated to Shanghai University of TCM, Shanghai 201203, China.
Download: HTML     PDF(286KB)
Export: BibTeX | EndNote (RIS)      

Highlights:

Based on the published literatures of TCM treatment for cancerous fever, this study analyzed the principles of differentiation and prescription in treating cancerous fever by metrology statistics and Logistic regression analysis. It provided a reference for clinical treatment of cancerous fever.

Abstract

To investigate the principles of differentiation and prescription of traditional Chinese medicine (TCM) treatment for cancerous fever by logistic stepwise regression and literature investigation, the following databases were searched (from inception to June 30th 2016): CNKI, CSPD, CBM, PubMed, MEDLINE, EMBASE. According to the inclusion and exclusion criteria, literatures about TCM in the treatment of cancerous fever were screened. The frequency about cancerous fever of differential syndrome types, formulas and herbs were analyzed by logistic multiple regression analysis. The model about syndrome types and formula application of cancerous fever was established. The result showed formula prescriptions used most frequently were Qing-Hao-Bie-Jia decoction, Xiao-Chai-Hu decoction, Xue-Fu-Zhu-Yu decoction, Bai-Hu decoction, San-Ren decoction. The main syndrome types of cancerous fever were as follows: Toxic heat flourishing type, Yin deficiency type, Stagnation of damp-heat type, Qi-Yin deficiency type, Liver meridian depressed-heat type, Blood stasis type and Yang deficiency type. Based on regression equation of the syndrome types, the corresponding herbs of this seven syndrome types were Radix Bupleuri, Radix Paeoniae Alba and Scutellaria Baicalensis Georgi; Radix Bupleuri and Cortex Moutan; Radix Paeoniae Rubra and Radix Angelicae Sinensis; Rhizoma Pinelliae, Cortex Lycii Radicis and Radix Paeoniae Alba; Herba Artemisiae Annuae, Gypsum Fibrosum and Poria Cocos; Rhizoma Anemarrhenae, Scutellaria Baicalensis Georgi and Radix Codonopsis; Radix Bupleuri respectively. The results of Logistic regression analysis and frequency of herbs statistics can provide reference for differentiation and treatment of cancerous fever in clinical.



Key wordsTraditional Chinese Medicine      Cancerous fever      Logistic regression analysis      Literature investigation     
Published: 05 January 2017
Corresponding Authors: Zhu Hui-Rong     E-mail: zhu_huirong@126.com.
About author: §These authors contributed equally to this work. Executive Editor: Cui-Hong ZhuEnglish Editor: Xiao-Hui Liu
Cite this article:

Xu Wei, Chai Ni, Cheng Yue-Lei, Yang Qiong, Zhu Hui-Rong. Analysis on the principles of differentiation and prescription of traditional Chinese medicine in the treatment of cancerous fever. Traditional Medicine Research, 2017, 2(1): 41-50. doi: 10.12032/TMR201705036

URL:

https://www.tmrjournals.com/tmr/EN/10.12032/TMR201705036     OR     https://www.tmrjournals.com/tmr/EN/Y2017/V2/I1/41

Syndrome types Prescription (n) Frequency rate (%)
Toxic heat flourishing type 35 17.24
Yin deficiency type 33 16.25
Stagnation of damp-heat type 32 15.76
Qi-Yin deficiency type 22 10.83
Liver meridian depressed-heat type 20 9.85
Blood stasis type 20 9.85
Yang deficiency type 13 6.4
Table 1 Statistical frequency of syndrome types of cancerous fever

Herbal formulas
Syndromes Types
Total
Toxic heat flourishing Yin deficiency Stagnation of damp-heat Qi-Yin deficiency Liver meridian depressed-heat Blood stasis Yang deficiency
Qing-Hao-Bie-Jia decoction 0 16 0 3 0 0 0 19
Xiao-Chai-Hu decoction 0 0 0 0 13 0 0 13
Xue-Fu-Zhu-Yu decoction 0 0 0 0 0 13 0 13
Bai-Hu decoction 12 0 0 0 0 0 0 12
San-Ren decoction 0 0 10 0 0 0 0 10
Qing-Gu-San decoction 0 7 0 0 0 0 0 7
Bu-Zhong-Yi-Qi decoction 0 0 0 6 0 0 0 6
Dan-Zhi-Xiao-Yao decoction 0 0 0 0 5 0 0 5
Hao-Qin-Qing-Dan decoction 0 0 5 0 0 0 0 5
Zhu-Ye-Shi-Gao decoction 0 0 0 3 0 0 0 3
Huan-Lian-Jie-Du decoction 3 0 0 0 0 0 0 3
Table 2 the frequency of prescription used more than 3 times in 175 prescriptions treatment for cancerous fever

Sort
Syndrome types
Toxic heat flourishing Yin deficiency Stagnation of damp-heat Qi-Yin deficiency Liver meridian depressed-heat Blood stasis Yang deficiency
1 Radix Glycyrrhizae
24 (68.57%)
Radix Rehmanniae
29 (87.87%)
Scutellaria Baicalensis Georgi
23 (71.88%)
Radix Astragali Seu Hedysari
17 (77.27%)
Scutellaria Baicalensis Georgi
20 (100%)
Radix Paeoniae Rubra
19 (95%)
Radix aconiti lateralis preparata
12 (92.3%)
2 Gypsum Fibrosum
23 (65.71%)
Carapax Trionycis
29 (87.87%)
Rhizoma Pinelliae
19 (59.38%)
Radix Codonopsis
15 (68.18%)
Radix Bupleuri
19 (95%)
Semen Persicae
17 (85%)
Radix Glycyrrhizae
12 (92.3%)
3 Rhizoma Anemarrhenae
22 (62.85%)
Rhizoma Anemarrhenae
29 (87.87%)
Semen Coicis
19 (59.38%)
Radix Glycyrrhizae
13 (59.09%)
Rhizoma Pinelliae
16 (80%)
Radix Bupleuri
16 (80%)
Rhizoma Zingiberis
10 (76.92%)
4 Radix Rehmanniae
15 (42.85%)
Herba Artemisiae Annuae
27 (81.81%)
Talcum
15 (46.88%)
Rhizoma Atractylodis Macrocephalae
12 (54.55%)
Radix Codonopsis
11 (55%)
Radix Angelicae Sinensis
15 (75%)
Radix Astragali Seu Hedysari
8 (61.54%)
5 Flos Lonicerae
14 (40%)
Cortex Moutan
27 (81.81%)
Radix Glycyrrhizae
13 (40.63%)
Radix Bupleuri
11 (50%)
Ziziphus jujuba
11 (55%)
Radix Rehmanniae
14 (70%)
Rhizoma Atractylodis Macrocephalae
8 (61.54%)
6 Radix Scrophularia
12 (34.28%)
Radix Ophiopogonis
22 (66.67%)
Cortex Magnoliae Officinalis
13 (40.63%)
Radix Angelicae Sinensis
10 (45.45%)
Rhizoma Zingiberis Recens
10 (50%)
Achyranthes bidentata Blume
14 (70%)
Radix Paeoniae Alba
7 (53.85%)
7 Rhizoma Coptidis
12 (34.28%)
Cortex Lycii Radicis
19 (57.58%)
Radix Bupleuri
12 (37.5%)
Radix Rehmanniae
8 (36.36%)
Radix Glycyrrhizae
7 (35%)
Radix Glycyrrhizae
13 (65%)
Rhizoma Anemarrhenae
6 (46.15%)
8 Scutellaria Baicalensis Georgi
11 (31.42%)
Radix Stellariae
19 (57.58%)
Semen Armeniacae Amarum
12 (37.5%)
Radix
Ophiopogonis
8 (36.36%)
Hedyotis diffusa
7 (35%)
Fructus Aurantii
12 (60%)
Pericarpium Citri Reticulatae
6 (46.15%)
9 Radix Ophiopogonis
11 (31.42%)
Radix Glycyrrhizae
14 (42.42%)
Cardamom
12 (37.5%)
Pericarpium Citri Reticulatae
8 (36.36%)
Radix Paeoniae Alba
6 (30%)
Cortex Moutan
11 (55%)
Radix Pseudostellariae
6 (46.15%)
10 Forsythia suspense
11 (31.42%)
Radix Scrophulariae
10 (30.30%)
Herba Artemisiae Annuae
12 (37.5%)
Rhizoma Cimicifugae
8 (36.36%)
Gardenia jasminoides Ellis
5 (25%)
Carthamus tinctorius
11 (55%)
Radix Angelicae Sinensis
5 (38.46%)
11 Cortex Moutan
10 (28.57%)
Radix Paeoniae Rubra
9 (27.28%)
Hedyotis diffusa
11 (34.38%)
Poria Cocos
6 (27.27%)
Radix Curcumae
5 (25%)
Rhizoma Chuanxiong
10 (50%)
Cortex Cinnamomi
5 (38.46%)
12 Hedyotis diffusa
10 (28.57%)
Herba Dendrobii
6 (18.18%)
Folia Bambosae
11 (34.38%)
Radix Pseudostellariae
6 (27.27%)
Cortex Moutan
5 (25%)
Rhizoma Curcumae
7 (35%)
Radix Rehmanniae
4 (30.77%)
Table 3 Statistics results about the frequency of the herbs of treatment for cancerous fever
Herbs β S.E. Wald P OR
Radix Glycyrrhizae -1.736 0.811 4.588 0.032 0.176
Radix Bupleuri 4.236 1.334 10.087 0.001 69.165
Radix Paeoniae Alba 2.423 1.190 4.149 0.042 11.279
Gypsum Fibrosum -3.557 0.793 20.146 <0.0001 0.029
Scutellaria baicalensis Georgi 3.150 1.203 6.857 0.009 23.345
Radix et Rhizoma Rhei -2.830 1.202 5.544 0.019 0.059
Folia Bambosae 4.822 1.758 7.521 0.006 124.270
Table 4 Toxic heat flourishing type
Herbs β S.E. Wald P OR
Radix Rehmanniae -4.214 1.595 6.975 0.008 0.015
Radix Bupleuri 5.077 1.411 12.951 <0.0001 160.310
Cortex Moutan 3.899 1.632 5.707 0.017 49.337
Herba Artemisiae Annuae -3.407 1.198 8.087 0.004 0.033
Carapax Trionycis -6.524 1.586 16.925 <0.0001 0.001
Table 5 Yin deficiency type
Herbs β S.E. Wald P OR
Scutellaria Baicalensis Georgi -2.752 0.838 10.788 0.001 0.064
Radix Paeoniae Rubra 3.607 1.590 5.148 0.023 36.842
Radix Angelicae Sinensis 2.862 1.299 4.856 0.028 17.500
Fructus Aurantii -2.852 1.093 6.807 0.009 0.058
Semen Coicis -4.941 1.131 19.090 <0.0001 0.007
Cortex Magnoliae Officinalis -1.990 0.962 4.275 0.039 0.137
Table 6 Stagnation of damp-heat type
Herbs β S.E. Wald P OR
Radix Astragali Seu Hedysari -4.758 1.672 8.094 0.004 0.009
Rhizoma Pinelliae 4.674 1.498 9.734 0.002 107.144
Radix Codonopsis -5.281 1.506 12.295 <0.0001 0.005
Cortex Lycii Radicis 7.060 3.300 4.578 0.032 1164.713
Radix Paeoniae Alba 5.959 1.989 8.980 0.003 387.391
Radix Pseudostellariae -6.844 1.852 13.651 <0.0001 0.001
Herba Lophatheri -5.980 1.921 9.687 0.002 0.003
Table 7 Qi-Yin deficiency type
Herbs β S.E. Wald P OR
Scutellaria baicalensis Georgi -1.994 0.678 8.660 0.003 0.136
Herba Artemisiae Annuae 4.540 1.769 6.589 0.010 93.681
Rhizoma Pinelliae -2.934 0.930 9.967 0.002 0.053
Gypsum Fibrosum 4.318 1.825 5.601 0.018 75.064
Poria Cocos 2.472 1.092 5.123 0.024 11.852
Rhizoma Zingiberis Recens -3.412 0.873 15.279 <0.0001 0.033
Table 8 Liver meridian depressed-heat type
Herbs β S.E. Wald P OR
Radix Bupleuri -1.420 0.713 3.968 0.046 0.242
Rhizoma anemarrhenae 3.353 1.200 7.805 0.005 28.575
Scutellaria baicalensis Georgi 2.133 0.917 5.417 0.020 8.443
Radix Astragali Seu Hedysari -3.785 1.175 10.379 0.001 0.023
Radix Codonopsis 2.594 1.033 6.311 0.012 13.390
Radix Paeoniae Rubra -4.723 1.122 17.711 <0.0001 0.009
Table 9 Blood stasis type
Herbs β S.E. Wald P OR
Radix Bupleuri 1.656 0.739 5.022 0.025 5.236
Rhizoma Atractylodis Macrocephalae -1.476 0.599 6.076 0.014 0.229
Radix Pseudostellariae -1.615 0.672 5.771 0.016 0.199
Cortex Phellodendri -1.468 0.685 4.600 0.032 0.230
Ramulus Cinnamomi -2.575 0.674 14.571 <0.0001 0.076
Table 10 Yang deficiency type
1.   Woolery WA, Franco FR.Fever of unknown origin: keys to determining the etiology in older patients. Geriatrics 2004 (10): 41-45.
2.   Tamburini M.Health-related quality of life measures in cancer. Ann Oncol 2001, 12(Suppl 3): S7-10.
3.   Myers JS.Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Forum 2008, 35(5): 802-807.
4.   Hureau M, Chaumard-Billotey N, Emard M, et al.Patient education in the prevention of febrile aplasia in oncology. Rev Infirm. 2014, 197: 23-25.
5.   Reavley N, Pallant JF, Sali A.Evaluation of the effects of a psychosocial intervention on mood, coping, and quality of life in cancer patients. Integr Cancer Ther 2009, 8(1): 47-55.
6.   Saeedisaedi H, Shahidsales S, Koochakpour M et al. Evaluation of Emotional Distress in Breast Cancer Patients. Iran J Cancer Prev 2015, 8(1): 36-41.
7.   Myers JS.Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Forum 2008, 35(5): 802-807.
8.   Golant M, Altman T, Martin C.Managing cancer side effects to improve quality of life: a cancer psychoeducation program. Cancer Nurs 2003, 26(1): 37-44.
9.   Nakagawa S, Toya Y, Okamoto Y, et al.Can anti-infective drugs improve the infection-related symptoms of patients with cancer during the terminal stages of their lives? J Palliat Med 2010, 13(5): 535-540.
10.   Mercadante S, Valle A, Porzio G, et al.Prognostic factors of survival in patients with advanced cancer admitted to home care. J Pain Symptom Manage 2013, 45(1): 56-62.
11.   Breen M, Coombes L, Bradbourne C.Supportive care for children and young people during cancer treatment. Community Pract. 2009, 82(9): 28-31.
12.   Binz P, Bodmer N, Leibundgut K, et al.Different fever definitions and the rate of fever and neutropenia diagnosed in children with cancer: A retrospective two-center cohort study. Pediatr Blood Cancer 2013, 60(5): 799-805.
13.   Lewis MA, Hendrickson AW, Moynihan TJ.Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin 2011, 61(5): 287-314.
14.   Larsen J, Nordström G, Björkstrand B, et al.Symptom distress, functional status and health-related quality of life before high‐dose chemotherapy with stem‐cell transplantation. Eur J Cancer Care (Engl) 2003, 12(1): 71-80
15.   Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs2002, 62 Suppl 1:1-15.
16.   Nuñez AM.Fever of unknown origin in patients undergoing chemotherapy. Clin J Oncol Nurs 2001, 5(1): 34-45.
17.   Sanz Rubiales A, García Alvarez G, Centeno Cortés C, et al.Colony stimulating factors in chemotherapy induced neutropenic fever. An Med Interna 1998, 15(2): 100-104.
18.   Richardson JL, Marks G, Levine A.The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988, 6(11): 1746-1752.
19.   Ling Y.Traditional Chinese medicine in the treatment of symptoms in patients with advanced cancer. Ann Palliat Med 2013, 2(3): 141-152.
20.   Yantao J, Liang C, Yingjie J, et al.Forty cases of tumorous fever treated with TCM method of removing blood heat and dissipating blood stasis. J Tradit Chin Med 2006, 26(3): 202.
21.   Li HY, Qian LS, Feng SZ.Clinical observation on treatment of complications with Chinese medicine according to syndrome differentiation of post-bone marrow transplantation in 22 patients with leukemia. Zhongguo Zhong xi yi jie he za zhi 1997, 17(10): 581-583.
22.   Lin JJ, Jin CN, Zheng ML, et al.Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation. Chin J Integr Med 2005, 11(2): 104-110.
23.   Chen Y, Jiang TH, Ru WZ, et al.Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome. Chin J Integr Med 2014, 20(8): 585-590.
24.   Cheon S, Zhang X, Lee IS, et al.Pharmacopuncture for cancer care: a systematic review. Evid Based Complement Alternat Med 2014, 2014: 804746.
25.   Jacobson JS, Grann VR, Gnatt MA, et al.Cancer outcomes at the Hufeland (Complementary/Alternative Medicine) Klinik: A best-case series review. Integr Cancer Ther 2005, 4(2): 156-167.
26.   Fritz H, Flower G, Weeks L, et al.Intravenous Vitamin C and Cancer A Systematic Review. Integr Cancer Ther 2014, 13(4): 280-300.
27.   Bauer-Wu S, Lhundup T, Tidwell T, et al.Tibetan Medicine for Cancer An Overview and Review of Case Studies. Integr Cancer Ther 2014, 13(6): 502-512.
28.   Yoon SW, Jeong JS, Kim JH, et al.Cancer Prevention and Therapy Integrating Traditional Korean Medicine Into Modern Cancer Care. Integr Cancer Ther 2014, 13(4): 310-331.
29   29.Hu KW, He XL. Chinese medicine cancer fever diagnosis and treatmentguidelines (Draft) [C]. ITAC International Chinese medicine Oncology Conference (2007).
30.   National pharmacopoeia commission. Pharmacopoeia of the people's Republic of China. Beijing: China Medical Science and Technology Press (2010).
31.   Wicke RW, Cheung CS.Traditional Chinese Medicine Analysis. Integ Cancer Ther 2002, 1(2): 192-200.
32.   Wicke RW, Cheung CS.Principles for applying traditional Chinese medicine to cases of cancer. Integr Cancer Ther 2002, 1(2): 175-178.
33.   Wang N, Feng Y, Cheung F, et al.A Chinese Medicine Formula Gegen Qinlian Decoction Suppresses Expansion of Human Renal Carcinoma With Inhibition of Matrix Metalloproteinase-2. Integr Cancer Ther 2015, 14(1): 75-85.
34.   Chen FM, Zhao WK, Xu PC.Comparative study on the regulatory effects on senescence related cell cycle gene expression by TCM principles of tonifying shen, invigorating pi benefiting qi, and activating blood circulation. Zhongguo Zhong xi yi jie he za zhi 2003, 23(11): 837-840.
35.   Guo H, Liu JX, Xu L, et al.Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. Integr Cancer Ther 2011, 10(2): 127-137.
36.   Charles HL.Traditional Chinese Medical Analysis. Integr Cancer Ther 2002, 1(1): 55-56.
37.   Yance DR.Western Herbal-Nutritional Analysis. Integr Cancer Ther 2002, 1(1): 56-58.
38.   Schmaltz JR, Agulnik M, Mullane MR, et al.Integrative Tumor Board: Colon Cancer with Liver Metastases. Integr Cancer Ther 2003, 2(2): 166-198.
39.   Xiong F, Jiang M, Huang Z, et al.A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells. Integr Cancer Ther 2014, 13(2): 152-160.
40.   Luo XQ, Xu YM, Tang Y.Pathological basis of qi-deficiency and blood stasis syndrome in patients with non-small cell lung cancer viewing from tumor metastasis related factors. Zhongguo Zhong xi yi jie he za zhi 2009, 29(10): 886-888.
41.   Wang XM, Yu RC, Wang YT.Study on advanced non-small cell lung cancer patients with Qi deficiency and blood stasis syndrome. Zhongguo Zhong xi yi jie he za zhi 1994, 14(12): 724-726.
42.   Yuan L, Zhang PT, Yang ZY.Study on qi deficiency syndrome distribution and quality of life in patients with advanced non-small cell lung cancer. Zhongguo Zhong xi yi jie he za zhi 2011, 31(7): 880-883.
43.   Tina K.Naturopathy. Integ cancer ther 2006, 5(2): 140-147.
44.   Park WH, Kang S, Piao Y, et al.Ethanol extract of Bupleurum falcatum Linne and saikosaponins inhibit neuroinflammation via inhibition of NF-κB. J Ethnopharmacol 2015, 174: 37-44.
45.   Park HM, Kim SY, Jung IC, et al.Integrative tumor board: a case report and discussion from East-West Cancer Center. Integ cancer ther 2010, 9(2): 236-245.
46.   Jongsoo J, Bongha R, Jinsung K, et al.Bojungikki-tang for cancer-related fatigue: a pilot randomized clinical trial. Integr Cancer Ther 2010, 9(4): 331-338.
47.   Xu L, Lao LX, Ge A, et al.Chinese herbal medicine for cancer pain. Integr Cancer Ther 2007, 6(3): 208-234.
48.   Hsu YL, Kuo PL, Weng TC, et al.The antiproliferative activity of saponin-enriched fraction from Bupleurum Kaoi is through Fas-dependent apoptotic pathway in human non-small cell lung cancer A549 cells. Biol Pharm Bull 2004, 27(7): 1112-1115.
49.   Chen JL, Chang CJ, Wang JY, et al.In vitro and in vivo effects of Jia-Wei-Xiao-Yao-San in human breast cancer MCF-7 cells treated with tamoxifen. Integr Cancer Ther 2014, 13(3): 226-239.
50.   McCulloch M, Broffman M, van der Laan M, et al. Lung cancer survival with herbal medicine and vitamins in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods. Integr Cancer Ther 2011, 10(3): 260-279.
[1] Su-Tong Liu, Su-Fang Zhang, Kai-Qi Su, Ying-Bin Luo, Zhi-Hong Fang, Yuan Fang, Jing Xu, Jian-Chun Wu, Yan Li. The effect of long-term traditional Chinese medicine treatment on disease-free survival of postoperative stage I-III lung cancer patients: a retrospective cohort study[J]. Traditional Medicine Research, 2019, 4(2): 91-98.
[2] Wei-Jie Xie, Yu-Mei Wu, Shuai-Shuai Chen, Jian Xu, Fang-Fang Yang, Yong-Ping Zhang, Xiao-Bo Sun. In vitro evaluation of transdermal permeation effects of Fu’s cupping therapy via six diffusion kinetics models[J]. Traditional Medicine Research, 2019, 4(1): 42-53.
[3] Liang-Jun Yang, Dao-Rui Hou, Ya Li, Zhi-Peng Hu, Yong Zhang. A network pharmacology approach to investigate the mechanisms of Si-Jun-Zi decoction in the treatment of gastric precancerous lesions[J]. Traditional Medicine Research, 2018, 3(6): 273-285.
[4] Jian Hao, Shi-Jun Li. Recent advances in network pharmacology applications in Chinese herbal medicine[J]. Traditional Medicine Research, 2018, 3(6): 260-272.
[5] Yue Ji, Jun-Chen Li, Jing-Yan Meng, Xue-Rou Yan, Jian-ang Li, Qing-Yun Zhao, Kang Yang, Chun- Liu. Study of dual-directional regulatory effect of Banxia (Pinellia ternata) and Huanglian (Coptis chinensis) drug pair on gastrointestinal movement of mice[J]. Traditional Medicine Research, 2018, 3(3): 148-156.
[6] Wen-Qi Huang, Zhu Yang, Dong-Xin Tang, Feng-Xi Long, Li Luo, Bing Yang, Juan Li, Jie Chen. Pharmacological intervention of traditional Chinese medicine for the quality of life in patients with colorectal cancer: a systematic review and meta-analysis[J]. Traditional Medicine Research, 2018, 3(2): 95-105.
[7] Li-Lin Yang, Jie Gao, Hai-Wang Wu, Song-Ping Luo. History of recurrent miscarriage in traditional Chinese medicine literature[J]. Traditional Medicine Research, 2018, 3(2): 62-69.
[8] Tian Ran, Dai Liang, Shang Hong-Cai, Li You-Ping, Bian Zhao-Xiang. How to establish precise proprietary Chinese medicine in post-marketing reappraisal?[J]. Traditional Medicine Research, 2017, 2(4): 155-160.
[9] Zhai Jing-Bo, Li Jiang, Chen Jing. The applications of Bayesian models in real-world studies of traditional Chinese medicine: a primer[J]. Traditional Medicine Research, 2017, 2(2): 88-93.
[10] Yang Xue, Wu Xiong-Zhi. The combination of disease and Zheng (syndrome) on the basic of differentiation of six channels: a new pattern of disease diagnosis and treatment of traditional Chinese medicine[J]. Traditional Medicine Research, 2017, 2(2): 100-104.
[11] Shang Hong-Cai, Wu Xiong-Zhi, Qiu Rui-Jin, Wang Ya-Han, Wang Yong-Yan. Traditional Chinese medicine should not be ignored during the development of precision medicine with Chinese characteristics[J]. Traditional Medicine Research, 2016, 1(3): 105-114.
[12] Liu Li-Juan, Zhou Chao, Song Fu-Cheng, Zhang Sen-Sen, Teng Wen-Jing, Zhuang Jing, Sun Chang-Gang, Si Hong-Zong. Molecular docking study on the molecular mechanism of rhaponticin for treatment of chronic myelocytic leukemia[J]. Traditional Medicine Research, 2016, 1(3): 122-127.
[13] Yang Dao-Zheng, Luan Xin-Yuan, Wang Shu-Bin. Epigenetic regulations of hematopoietic stem cells ageing and the regulation of traditional Chinese medicine[J]. Traditional Medicine Research, 2016, 1(2): 75-82.
[14] Cui-HongZhu, Hao Jian, Yang Xue, Wang Xiao-Dong, Xiong-ZhiWu. Complete response of hepatocellular carcinoma treated with traditional Chinese medicine treatment: A case report[J]. Traditional Medicine Research, 2016, 1(1): 52-57.